Karyopharm Therapeutics Inc. (KPTI) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
KPTI Revenue Growth
Revenue Breakdown (FY 2025)
KPTI's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
KPTI Revenue Analysis (2014–2025)
As of May 8, 2026, Karyopharm Therapeutics Inc. (KPTI) generated trailing twelve-month (TTM) revenue of $142.5 million, reflecting strong growth of +13.6% year-over-year. The most recent quarter (Q3 2025) recorded $44.0 million in revenue, up 16.1% sequentially.
Looking at the longer-term picture, KPTI's 5-year compound annual growth rate (CAGR) stands at +6.2%, indicating steady revenue expansion. The company achieved its highest annual revenue of $209.8 million in 2021.
Revenue diversification analysis shows KPTI's business is primarily driven by License and Service (98%), and Health Care, Other (2%). With over half of revenue concentrated in License and Service, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including PTCT (-53.3% YoY), FOLD (+20.0% YoY), and MGNX (+0.8% YoY), KPTI has underperformed the peer group in terms of revenue growth. Compare KPTI vs PTCT →
KPTI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| KPTICurrent | $143M | +13.6% | +6.2% | -62.1% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 MGNX | $150M | +0.8% | +8.9% | -48.7% | |
 ADMA | $510M | +11.0% | +64.6% | 37.5% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% |
KPTI Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $146.1M | +0.6% | $140.1M | 95.9% | $-90,707,000 | -62.1% |
| 2024 | $145.2M | -0.5% | $139.2M | 95.9% | $-119,443,000 | -82.2% |
| 2023 | $146.0M | -7.0% | $141.1M | 96.6% | $-129,540,000 | -88.7% |
| 2022 | $157.1M | -25.1% | $151.9M | 96.7% | $-142,202,000 | -90.5% |
| 2021 | $209.8M | +94.1% | $206.4M | 98.4% | $-98,271,000 | -46.8% |
| 2020 | $108.1M | +164.3% | $105.4M | 97.5% | $-171,850,000 | -159.0% |
| 2019 | $40.9M | +34.8% | $38.5M | 94.1% | $-189,275,000 | -462.9% |
| 2018 | $30.3M | +1790.1% | $-131,036,000 | -431.9% | $-179,883,000 | -593.0% |
| 2017 | $1.6M | +942.2% | $-105,668,000 | -6583.7% | $-130,538,000 | -8133.2% |
| 2016 | $154K | -38.4% | $-86,784,000 | -56353.2% | $-110,732,000 | -71903.9% |
See KPTI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KPTI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KPTI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKPTI — Frequently Asked Questions
Quick answers to the most common questions about buying KPTI stock.
Is KPTI's revenue growth accelerating or slowing?
KPTI maintains +13.6% revenue growth, in line with its 5-year CAGR of +6.2%. TTM revenue stands at $143M. Growth rate remains consistent with historical average.
What is KPTI's long-term revenue growth rate?
Karyopharm Therapeutics Inc.'s 5-year revenue CAGR of +6.2% reflects the sustained expansion pattern. Current YoY growth of +13.6% is near this long-term average.
How is KPTI's revenue distributed by segment?
KPTI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.